CAN FITE BIOPHARMA LTD-ADR (CANF)
US13471N3008 - ADR
We assign a fundamental rating of 2 out of 10 to CANF. CANF was compared to 568 industry peers in the Biotechnology industry. The financial health of CANF is average, but there are quite some concerns on its profitability. CANF has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year CANF has reported negative net income.
In the past year CANF has reported a negative cash flow from operations.
In the past 5 years CANF always reported negative net income.
In the past 5 years CANF always reported negative operating cash flow.
1.2 Ratios
CANF's Return On Assets of -128.91% is on the low side compared to the rest of the industry. CANF is outperformed by 82.12% of its industry peers.
CANF has a worse Return On Equity (-307.95%) than 75.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -128.91% | ||
| ROE | -307.95% | ||
| ROIC | N/A |
ROA(3y)-87.03%
ROA(5y)-114.94%
ROE(3y)-151.83%
ROE(5y)-244.41%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CANF does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CANF does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CANF has been increased compared to 1 year ago.
CANF has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CANF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CANF has an Altman-Z score of -40.83. This is a bad value and indicates that CANF is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -40.83, CANF is not doing good in the industry: 93.45% of the companies in the same industry are doing better.
CANF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -40.83 |
ROIC/WACCN/A
WACC9.57%
2.3 Liquidity
CANF has a Current Ratio of 2.93. This indicates that CANF is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CANF (2.93) is worse than 66.02% of its industry peers.
A Quick Ratio of 2.93 indicates that CANF has no problem at all paying its short term obligations.
The Quick ratio of CANF (2.93) is worse than 63.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.93 | ||
| Quick Ratio | 2.93 |
3. Growth
3.1 Past
CANF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.13%, which is quite impressive.
CANF shows a decrease in Revenue. In the last year, the revenue decreased by -8.27%.
The Revenue for CANF have been decreasing by -27.92% on average. This is quite bad
EPS 1Y (TTM)52.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-59.56%
Revenue 1Y (TTM)-8.27%
Revenue growth 3Y-0.88%
Revenue growth 5Y-27.92%
Sales Q2Q%-55.8%
3.2 Future
Based on estimates for the next years, CANF will show a very negative growth in Earnings Per Share. The EPS will decrease by -15.81% on average per year.
CANF is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.69% yearly.
EPS Next Y-1.01%
EPS Next 2Y6.34%
EPS Next 3Y-15.81%
EPS Next 5YN/A
Revenue Next Year36.48%
Revenue Next 2Y16.83%
Revenue Next 3Y2.69%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CANF. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CANF. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as CANF's earnings are expected to decrease with -15.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.34%
EPS Next 3Y-15.81%
5. Dividend
5.1 Amount
CANF does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CAN FITE BIOPHARMA LTD-ADR
NYSEARCA:CANF (12/18/2024, 8:07:11 PM)
After market: 1.31 -0.02 (-1.5%)1.33
-0.09 (-6.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap6.64M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -128.91% | ||
| ROE | -307.95% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.93 | ||
| Quick Ratio | 2.93 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)52.13%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-1.01%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-8.27%
Revenue growth 3Y-0.88%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y